BioChange has developed a breakthrough technology for tissue regeneration. A unique injectable scaffold that stimulates tissue repair and remodelling at the injected site. The scaffold is based on natural biomaterials designed for implantation using a minimally invasive procedure. It mimics the healthy Extra Cellular Matrix (ECM) and triggers the body to repair itself. 
Multiple long-term animal studies confirmed the safety and efficacy of the technology. The company is now selling products in the veterinary market and in tissue engineering research and is committed to start first clinical study in aesthetic dermatology in 2022. 
Several other products based on the CellFoam platform technology are in development to enrich our pipeline.

Health Care

Biotechnology

BioChange Ltd.

Ishay Attar

Iris Shichor

Yuval Eitan

Keren Sinik

Ofir Artzi

The Advisory Board at BioChange Ltd. provides strategic guidance and expert advice on the development and commercialization of the company's tissue regeneration technologies. Comprising experienced professionals in relevant fields, the board helps steer clinical studies, regulatory compliance, market entry strategies, and overall R&D direction to ensure the success and growth of the company's innovative pipeline.

Advisory Board

Leadership Team

Research and Development

Advisory Board

About

Team members

Other teams at BioChange Ltd.

Leadership Team

Research and Development